<SEC-DOCUMENT>0001193125-14-232752.txt : 20140624
<SEC-HEADER>0001193125-14-232752.hdr.sgml : 20140624
<ACCEPTANCE-DATETIME>20140611083030
ACCESSION NUMBER:		0001193125-14-232752
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140610
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140611
DATE AS OF CHANGE:		20140611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		14903571

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d743629d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;10, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16537</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-4370966</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>220 East First Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bethlehem, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18015-1360</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: 610-882-1820 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01 &#150; Entry Into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2014, OraSure Technologies, Inc. (&#147;OraSure&#148;) entered into a Master Program Services and Co-Promotion Agreement (the
&#147;Agreement&#148;) with AbbVie Bahamas Ltd., a wholly-owned subsidiary of AbbVie, Inc. (&#147;AbbVie&#148;). A copy of a press release announcing the Agreement is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Agreement, OraSure and AbbVie will co-promote the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> rapid HCV test in the
United States. OraSure has granted to AbbVie the exclusive right to promote, with OraSure, the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> HCV test in certain markets, and OraSure will provide certain additional services as
set forth in the Agreement. OraSure will retain responsibility for manufacturing and selling the test into all markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the exclusive
rights granted to AbbVie under the Agreement, OraSure will receive up to $75.0 million in exclusivity payments during the term of the Agreement, which extends through December&nbsp;31, 2019. In addition, upon achievement of certain performance-based
milestones, OraSure will be eligible to receive additional payments ranging from $3.5 million to $55.5 million annually during the life of the Agreement. The Agreement contains additional terms and conditions, including indemnification provisions,
typical of agreements of this type. The Agreement may be terminated by either party due to material breach by, or insolvency of, the other party, as well as by either party for convenience on or after December&nbsp;31, 2016 or, in certain
circumstances by AbbVie, after a change of control of OraSure. The foregoing is only a summary of certain of the terms of the Agreement and is qualified by reference to the entire Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 &#150; Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;11, 2014, the Company held a webcast conference call with analysts and investors, during which Douglas A. Michels, the Company&#146;s President and Chief Executive Officer, and Ronald H. Spair, the Company&#146;s Chief Financial Officer
and Chief Operating Officer, discussed the recently announced Agreement with AbbVie. A copy of the prepared remarks of Messrs. Michels and Spair is attached as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item and attached Exhibit shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such
a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report or attached Exhibit. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 &#150; Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June 11, 2014, announcing that OraSure has entered into a Master Program Services and Co-Promotion Agreement with AbbVie.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prepared Remarks of Douglas A. Michels and Ronald H. Spair for OraSure Technologies, Inc. AbbVie Agreement Analyst/Investor Conference Call Held June 11, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signatures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">O<SMALL>RA</SMALL>S<SMALL>URE</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June 11, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jack E. Jerrett</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jack E. Jerrett</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Senior Vice President, General Counsel and Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Index to Exhibits </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June 11, 2014, announcing that OraSure has entered into a Master Program Services and Co-Promotion Agreement with AbbVie.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Prepared Remarks of Douglas A. Michels and Ronald H. Spair for OraSure Technologies, Inc. AbbVie Agreement Analyst/Investor Conference Call Held June 11, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d743629dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g743629ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Contact:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Media Contact:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ronald H. Spair</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Jennifer Moritz</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Zer0 to 5ive for OraSure Technologies</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">610-882-1820</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">917-748-4006</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Investorinfo@orasure.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><U>jmoritz@0to5.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>www.orasure.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORASURE TECHNOLOGIES ANNOUNCES NEW CO-PROMOTION AGREEMENT FOR ORAQUICK&reg; HCV RAPID ANTIBODY TEST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Investor Conference Call Scheduled Today for 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) - </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETHLEHEM, Pa. &#150; June&nbsp;11, 2014 &#150;</B> OraSure Technologies (NASDAQ: OSUR), a market leader in point of care diagnostics, announced today that
it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie under which AbbVie and OraSure will co-promote the Company&#146;s OraQuick&reg; HCV Rapid Test in the United States. The product will be used to test individuals
at-risk for hepatitis C (HCV). OraSure will be responsible for manufacturing and selling the product directly into all markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement,
OraSure has granted exclusive promotion rights to AbbVie for the OraQuick&reg; HCV test in certain markets and will provide certain additional services in support of HCV testing. In exchange for the exclusive rights granted to AbbVie, OraSure will
receive up to $75 million in exclusivity payments over the term of the agreement, which runs through December&nbsp;31, 2019. In addition, upon achievement of certain performance-based milestones, OraSure will be eligible to receive additional
payments annually over the life of the agreement. Further information regarding the agreement will be available in the Company&#146;s 8-K Report filed later today with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention (CDC), HCV is the most common chronic blood-borne infection in the United States, with
approximately 5&nbsp;million people infected. It is estimated that one in 30 Baby Boomers (adults born between 1945 and 1965) have chronic hepatitis C and up to 75% of the people infected with HCV are unaware of their infection. The CDC, the U.S.
Preventative Services Task Force (USPSTF), and the American Association for the Study of Liver Diseases (AASLD) have all issued guidance that recommends HCV testing for at-risk individuals including all Baby Boomers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;</B>We believe it is critical that at-risk individuals be tested for hepatitis C to prevent serious consequences from untreated infection,&#148; said
Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. &#147;This new collaboration allows us to educate healthcare professionals and the patients they treat about hepatitis C and provide them with a very important rapid
diagnostic tool.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The OraQuick&reg; HCV test is the first and only FDA-approved and CLIA-waived point of care test for detection of
HCV infection in at-risk individuals. The simple platform enables healthcare providers to deliver a diagnosis based on lab-accurate test results in 20 minutes, using fingerstick or venipuncture blood. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated Financial Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the new
co-promotion agreement announced today, the Company has updated its financial guidance to reflect the initial impact of this arrangement and is now projecting consolidated net revenues ranging from $26.0 to $26.5 million and a consolidated net loss
of approximately $0.08 to $0.09 per share for the second quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will host a conference call and audio webcast to discuss the co-promotion agreement today beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific
Time). On the call will be Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer and Chief Operating Officer. The call will include prepared remarks by management and a question and answer session.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to listen to the conference call, please either dial 844-831-3030 (Domestic) or 315-625-6887 (International) and reference Conference ID
#59796252 or go to OraSure Technologies&#146; web site, www.orasure.com, and click on the Investor Relations page. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call. A replay of the call
will be archived on OraSure Technologies&#146; web site shortly after the call has ended and will be available for seven days. A replay of the call can also be accessed until June&nbsp;18, 2014, by dialing 855-859-2056 (Domestic) or 404-537-3406
(International) and entering the Conference ID #59796252. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About OraSure Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies
designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions tests for detecting various drugs of abuse. The Company
sells the OraQuick&reg; In-Home HIV Test, the first and only rapid HIV test approved by the U.S. Food and Drug Administration for sale to the consumer over-the-counter market in the U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure&#146;s portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other
public health organizations, research and academic institutions, distributors, government agencies, physicians&#146; offices, and commercial and industrial entities. The Company&#146;s products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to improve and protect their health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on OraSure Technologies, please
visit www.orasure.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OraSure Technologies Forward-Looking Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements, including with respect to expected revenues and product usage. Forward-looking statements are
not guarantees of future </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are
not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements;
ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve
warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the
performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company&#146;s products; impact of
replacing distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the
full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to
customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on
product performance or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and
components; availability of related products produced by third parties or products required for use of the Company&#146;s products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry
forwards or other deferred tax assets; volatility of the Company&#146;s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual
property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including
the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to retain qualified personnel; exposure to product liability and
other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist
attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company&#146;s Securities and Exchange Commission filings, including its registration statements, Annual
Report on Form 10-K for the year ended December&nbsp;31, 2013, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that
forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d743629dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AbbVie Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Analyst/Investor Conference Call &#150; 8:30 a.m. EST </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;11, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Prepared Remarks of Douglas A. Michels and Ronald H. Spair </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Please see &#147;Important Information&#148; at the conclusion of the following prepared remarks.</U> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Introduction &#150; Doug Michels</U> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks
Rena. Good morning everyone and welcome to our call. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am extremely pleased to share with you that our Company has entered into a Master Program Services and Co-Promotion Agreement with AbbVie under which AbbVie
and OraSure will co-promote our Company&#146;s OraQuick&reg; HCV Rapid Test in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement is among the most significant in our
Company&#146;s history. First and foremost, it will enable us to broadly provide healthcare professionals and the patients they serve with a critically important rapid diagnostic test. Second, we believe this opportunity will be transformative for
OraSure and will drive significant growth in our HCV testing business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has never been a more critical time to know your HCV status. As we have
previously discussed on earnings calls, there are many positive trends occurring with respect to HCV testing and treatment, not the least of which is the development of new and more effective drug therapies. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the new agreement, we have granted exclusive rights to AbbVie to promote with us, the use of our
OraQuick&reg; HCV Rapid Test in certain markets and we will provide certain services in support of HCV testing. In exchange for those rights, OraSure will receive up to $75 million in exclusivity payments over the term of the agreement which runs
through December&nbsp;31, 2019. In addition, upon achievement of certain performance-based milestones, the Company will be eligible to receive additional payments ranging from $3.5 million to $55.5 million per year over the life of agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hepatitis C is the most common chronic blood-borne infection in the United States and the Centers for Disease Control and Prevention estimates that one in 30
baby boomers &#150; adults born between 1945 and 1965 &#150; have a chronic infection. Perhaps most alarming is that up to 75% of people infected with HCV are unaware of their infection which is why the CDC, the U.S. Preventative Services Task
Forces and the American Association for the Study of Liver Diseases have all issued guidance that recommends HCV testing for at-risk individuals including all baby boomers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is critical that at-risk individuals be tested for hepatitis C to prevent potentially serious consequences from undiagnosed and untreated infection.
Hepatitis C is the leading cause of liver cancer and liver transplants. Our OraQuick&reg; Rapid HCV Test, the only FDA approved and CLIA-waived point of care test, enables healthcare providers to deliver a diagnosis based on lab-accurate test
results in just 20 minutes, using a fingerstick or venipuncture blood sample. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With that, let me turn the call over to Ron who can share some financial
highlights associated with the agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Agreement Financial Highlights &#150; Ron Spair</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks Doug, and good morning everyone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Doug referenced, in exchange for providing exclusive co-promotion rights to AbbVie for the OraQuick&reg; HCV
test in certain markets, OraSure will receive up to $75 million in exclusivity payments over the term of the agreement which runs through December&nbsp;31, 2019. We plan on recognizing the exclusivity payments ratably on a monthly basis over the
life of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, upon achievement of certain performance-based milestones, the Company will be eligible to receive additional payments
ranging from $3.5 million to $55.5 million annually over the life of agreement. It is important to note that the first potential recognition of milestone revenues would occur during 2015 under this component of the agreement. We expect the success
we have under this component of our relationship with AbbVie to ramp over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also contains termination, indemnification and other
provisions typical for agreements of this type. Additional information about the agreement can be found in our 8-K report, which was filed shortly after the start of this call. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we look out over the balance of the year, in addition to recognizing incremental revenues, we will be investing in various promotional programs that we
will pursue with AbbVie. These programs will require bringing on additional personnel to staff new initiatives and incurring programmatic expenses. We will be disclosing more details of the specific programs as they are launched over the next
several months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consequently, we are revising our guidance for the second quarter to include the anticipated new revenues and expenses from the AbbVie
collaboration. We now are projecting consolidated net revenues of between $26.0 million and $26.5 million and a consolidated net loss in the range of $0.08 to $0.09 per share for the second quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we take a somewhat longer view of the business, this exciting opportunity with AbbVie, along with the changes
that we have announced with our HIV-OTC program and the expected termination of certain patent royalties on sales of our professional and OTC HIV products beginning in early 2015, are expected to drive the Company to full-year profitability in 2015.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And, with that, I will now turn the call back over to Doug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Conclusion &#150; Doug Michels</U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thanks Ron.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is truly a significant milestone for our Company and a major step in achieving our vision for this amazing product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I would like to thank all the people at AbbVie and OraSure who worked so hard to make this agreement a reality. It is a great achievement for each of our
respective companies. More importantly, we now have the opportunity to make a significant impact on those patients at risk for HCV, especially those who are unaware they are infected and face potentially serious health consequences from going
undiagnosed and/or untreated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">And with that, I will now open the floor to your questions. Operator please proceed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>[Q&amp;A session] </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Final Conclusion
&#150; Doug Michels</U> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for participating on today&#146;s call and for your continued interest in OraSure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Important Information </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements
are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to
market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing
and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit
observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical
activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company&#146;s products; impact of replacing distributors;
inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full benefits of future
acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from
new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based on product performance or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution
channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company&#146;s products; history of losses and ability to achieve
sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company&#146;s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty
and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and
manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of
capital; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and
ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company&#146;s Securities and
Exchange Commission filings, including its registration statements, Annual Report on Form 10-K for the year ended December&nbsp;31, 2013, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to
provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to
update these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g743629ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743629ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P$T`P$1``(1`0,1`?_$`-\``0`!!`,!`0$`````
M```````'!@@)"@$$!0(#"P$!``("`P$!``````````````0'!08!`P@""1``
M``8!`P(#!0,%"@@/`````0(#!`4&!P`1"!()(1,4,2(5%@I!43)A(QA8&7%"
M,R25UA?7.!J!H;'!HR:V>&*24W-DE+4V5G>W*"DY*A$``@$#`P$&`08&"@\$
M"P$``0(#`!$$$@4&(3%!42(3!V&!D3(4%19Q0B/350BAL5)B<I*BLW48\,'1
M@K+24W.CPS1TM#8W,R0U1>'QPD-C@Y,E)G8G./_:``P#`0`"$0,1`#\`SK=X
M#N\<C>WOGS&V*<.8KQ#>Z_<\0-LA24GD)M=5Y9I,+72U5M1BS-6K5`LRQY64
M&BH`*)G5\Q0_O=.P!Z"]H_:7CO/]AR=UWC+RX)X<LQ!8C&%*B.-[G7&YO=B.
MAM8#I5$>ZGNCR+@V]0;;L^'!DP2XHE+.LC$,9)$(\LB"P"J>\]36)O\`O-O.
MK]73C)_)^5_ZQ]6K_5KX-^DMR_C0?F:K#^L-SG]%XG\2;\_3^\V<ZOU=.,G\
MGY7_`*Q]<_U:^#_I'<OG@_,T'ZPW.?T7A_Q)OS]?1/J:N=JAR)I\<N,QU%#E
M333)&Y8.=10Y@*1-,A<CB8YSF$```#<1'7RWZMG!5%SN6XV'[Z#\S7(_6%YV
MQTC:L.Y_>3?GZ^1^ILYUE$0-QSXRE,4PE$#1^5RB!@'80,!LCATB`^`[^S7/
M]6S@UK_:6X_QH/S-/ZPO.KV.UX=_X$WY^NY(?4N\]HI\\C)'C9QH:/X]RLS>
MM58_*P*MW+<XIK(J`&2!`#IG*(#XZ^(_U<.!S1K+'N6XF-@"#>'J#_\`)KLF
M_6!Y[!(T,NU8@D4V(T2]".[I/74'ZFKG8&PCQRXRAU!U%WCLL!U%W$`,7?(P
M=11$/`0\!U]C]6S@I[-RW'^-!^9KK/ZPO.A_Y5B?Q)OS]<?WFWG3^KIQD_D_
M*_\`6-I_5KX/^DMQ^>#\S7']8;G/Z+Q/XDWY^N/[S;SJ_5TXR?R?EC^L?3^K
M7P;]);C_`!H/S-/ZPW.OT7B?Q)OS]7!\3?J$^9&>N4''S"-NP1QZA*MEO+]$
MQ[89B`8Y+)-Q</:)YI%R#Z(/(WQ]'DD6K9<QTA6152ZP#J*(>&M?Y9[`\/V'
MC&X;WB9^?)DXF)+*BL8=+,BE@&M$#8D`&Q!M6>XO[Y\PWOD6#L^9MV+'C965
M%$S!)055W"L03,P!`)(N"+BMP37DBO5%-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5J+?4&4CYGY5X:
M>>4!_(X^-6O5T]6VV1[NKM_I->J_8?,.-QC,0=^>3_HHZHKW3VQ,[>\>1A<C
M%`_TCFL#HXE`/'T_^C'_`";:N[[5;QJLAQ^+]R*_1'$[<JJ)W+591J"B9G)&
MI2@Y,VZRBN#85`%,'`I;]'5[O5MOX:^6W20J0A\UNE^R_P`?A7TO'X-0+IY;
M];=M5ID'CA-8RLB+!0I'2#F+AKE2K&U1.6/LU7FFY)6L6:,.8/X-RGL19/<3
MM7B*S<^RB1@"%M_(HMSQBZ]&#-'(A/5'4Z71OP=Q_&4AAT(J3E<8&%.%`!%E
M=&'8RGJC#^SH01VBIKY=<6VE+RS&SD!'%1I.<Z11,X4?R$MFZ,?DV(:R<[#H
M"&Y/]7;D:09=(#[B:1-]MP#6&XGR>3,VIH)VOFX,TN-+?M)A8JK'^''I;Y36
M1W_BT$6X">%!]7RD29.G3\H+LOAT?4!X"U5)S>XNOH+FKF/']>B!5?SE_@QK
ML>DW,`N7E\AJ[)1K=),I0$?/D)OI``#VCKHX7R=9^&8>X3M9(\=M9/<(F<$_
M(JWKMY)Q9!R/(@B4:GE&D?%PI_;-1SRAX_1U+S[?,95QIZQCC-]!8I9&9MS+
M*RDI1X"'K$RZ011*8Z[B8M3-XL4I0$QCK;>(ZG\9WZ7,V*#<\@V;)#3F_32)
M69U!\`J%1^`5%WOCD$6YR8D2W2'3$/CH4*3\K`GY:C?(_&UWC:UNZ/+`FK9J
M\V8MK@U2*4Z$):7#8CV4K)52;@LZK8N2,WAM]@?I+D#W2`(Y+;>1KN.(,V&_
MU:0DH>]D!LK_``#VU+^]*GM-JAY?%XL28XS@>JH`<>#=ZW_>]A^(-4+_`$2C
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MK325<%+Y:*J@>)`,(";;PWV'5H?;$?J>D6'J6O:_6WX.^M3^S3IU!;+XU</3
M>+L1GJ)-%5-)C7<Z0K%19.L.!185[,44S3,HJZKZZ@IMH#)$>W*/J&9NEE+)
M%\],45P6`^O9G)9]@F]7+U2[&[?3%R^.QZ`,.UH2>QK:T/E.H6(R4.S1;BFF
M*RYZCL[%D'B/!QWCHK=HL;U.&*>.*W(/#-HXWV*+/#9TP.YG+=A<\VW-'R+N
MNR+PJM]Q'*>J\I9!JG.G!\R(<!!LZ=F.'2EYO5@]TY`G'MYBY'C,)-DSPJ9&
M@W4.H_)3K;H3I\K>*K;J;5/Q=J.XX+[7,ML['):/5T.DF[1GX:NH\":ERW<<
MULP\%>.=A5AU4KUQMOCW&UD;.6XIR250=7E.-?1SPBFRQ#0*RT>KY8A^:3!4
M?`-]8K$Y`NT<WW&`.#@;E`)D([/4$>H$=WF\X^)M4R?:_KNPXSD?]XQ9-!OV
MA=5B/DZ'X=:NLN_%MC;NZ)`92DV)#UFH8UJ^59)<Z9?*4G*DB]J5=3.)@Z3*
MI23!NYV]NS4?NUJN%R9L7VRDVN(GZS+E/`!^]>TC_(02O]]65GVE9N5+FN/R
M:1*Y/Q6ZK^S8_)5CV#L$-H)YF?GSDN(1>M:Y9KA8,.0<HD51.WY9L,\_^`3R
MJ"Q3`ZBJQ,2"9TMP$%'29C^QL.^Z[UO;3KA<"VURKR1QID,I^A`B#6MQV,Z@
MW\%L/QNF#P=M6-Y^0Y0N%=FC!_&D8FQ^(4GI\?X-6EU'BA+7"(L.9LH2+ZOX
MY0E'CF:MBZ)7%ER%;I%PN]6K-$9.A`LS9)=Z=0SAXI_$HX@G67,82>4;;,SE
M$6'-'LVUJLFY%0%C!LD2*`-<I'T546LOTGZ`6O>L1#LAG1LW,)7&#=6MYG8]
MR^)/6Y[`.I[+5$$SBM&1DG3MC`-X-@JITL(EL95PG'LR`!&S8[Q</42#DJ8!
MYKA38ZZHF/L4!`H9F'<6BB"22&22W5CTN>\V'0#P`[!T^-09,!'<LJ!5[AX#
MN[>W\)[:F[B=BI6+Y0<>Y(6NP,,P45WUB3\((SC4_5[-@VVUAN5[D)>,;A'?
MMPY1_)-3MIP`FZ8S@6M,A_9K<##V!^X&O)0[*N.N=*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5C,YL8
MS/=LCU21*V%;TM*38]0%W'?X[+K](#L/_+?X]65PO<AA;=*A-KS7_DJ*US><
M7U\A6\$M^R:M:@<1VBE219*);K1ZRB?E.6[U@1S&2K(X@*C"6C'Z"L?+1RX>
M!DEB'(/M#8P`(;-D[KB9\7I2G4O<0;,I\58&ZL/$=:QT6%)`VN,$-X=Q^!!%
MB*G:$X]8XR.NSE:F13"V5H]PB_:,X]5T>GOY-HH59%_7#JJ*24"Y!4G6"":I
MP2'P(0Y=:]D;_N>V@PYG_?=I8:2382!3TL_8&'=>W7Q!J<FVXV1YX?R.4#<?
MN21WCO'C8'Y*NXBL5/;/,UB[7"&0JN=:$H@0EWA$TQB;Q$D3,T<(29FO0608
M2D>H=)=!4$W+0YNI+8FQ=:C+N:XL,N#AN9=CR`?R3_2C;MN+]05:Q!%PP[>O
M6LJN+ZCI/*-&:A^D.QA\?$$=W:*GYI2:TS3LR*,4U!M<)(TQ861DRF9/Y-9H
MT9.GJC<0`GJ'B+%+S3!MYAR=8^\(B.%;*R&$8+G5$NE#W@7)`OX`DV\.SLJ:
M(HQJZ#SFY^)L!?\`8KNR=;C),)4YT0;OIB#/7G<FW`I'_P`+-ZPQ$$UQ`1("
M*L@JH3P\#GWU\1S21E+'R(^L#NU=.ORV`/PKEHU8-?M9;7[[?V&H&R;@RFV>
M$I%7G42QN'L;H)R`U")*LD>>D&"'H89@X!O^>%@S;&5$2)[N':[CVE'<PYK;
M=ZS<2>?*@.K=\DZ?4;\4,;L1?I<D#J?*H'?4/)PH9HTB<6Q(^ND=]A8#\';V
M=2:M8R=@RTY;?L9VZ'C,48IJK<8VDU=5`HKQ,0'0&T95X\2%5FY$A"BH)Q3$
M``I`#H+X[5M>^8VT1M!A:\S=I3>5QV,WQ<_B#X7ZW)ZUC<G`DRVU36BQEZ*/
M`?!1W_\`JJWVPX=K*)%(BC55PUC=A3<6.Q`D_M4P&VQS@0A?AM>9*>T$&J?G
M"'@HL;Q+K8\7=<MK3;A->3M")T1?[;GXL;>`%8Z3#B!T0)Y?$_2/]H?@`OXF
MN[AS"9X;+6-I868D",NM?>]8$$.GT\@BIU>S[-M?.];R)MHR8K_2@<?.*YP\
M#1E1M;L<5F8L%DKM1A)"QVR>AJQ7H=H9]+SUADV4+"Q3-,2E4=R4K(KMF#!L
M0QP`3JJ$*`B'CJFX()LJ9<?%1Y)W-E5069CX!1<D_`"MLEFAQH3/D.J0H+LS
M$*H'B2;`#XFJ4QSF+$F8(]W+8ERACS)\7'N2LY"1Q[<ZY<V+!V<ICD:O7=<D
M9%!HX4(01*10Q3&`!$`$-2MPVO<]ID6'=<:?&E87"RQO&2/$!P"1\14;!W/;
M=TC,NV9$&1$#8F*19`#X$J38].^I'U`J=32E1-D#/>#,32,5$93S-BK&LM.`
M!H6+OV0JE3Y&6(*QFX*1K*PRT>Y>I>>42=293%ZPVWWUD\#9-YW6-I=LQ,K)
MB3Z1BB>0+W^8HI`Z=>M8[-WC:=M=(]QRL?'D?Z(DD1"W\$,P)^2I2;.6SQ!)
MRT71=-ETDET'#=0BR"Z"Y"JHK(K)B9-5%9,P&*8HB4Q1`0';6-(()4]&!L1X
M'PK(`A@&4W4]AK]]<5S32E-*515PR5CG'GP_Y_O]*H_Q87(17SA:H*L_$Q9@
MB+P(_P"-/V7K!:@Y3\SR^KH\PO5MU!O,Q-NW#/U#!@FF*VOZ:,]K]E](-KV-
MK]MJB96?@8(4YL\,(:]M;JE[=MM1%[7%[>->75\RX@N\J6"I>5<;V^<,W6>%
MAJO>:Q8)4S1L)`<.BQT3*.W8MD!4+UGZ.DG4&XAN&NS*VG=<&+ULW%R(8;VU
M/&ZK<]UV4"]=>-NNUYDGI8>3CRRVOI21&-O&RDFU23K'U/K@1`H"(CL`>T=*
M52D)?*/99:;@:Y<JK8)VM.`:V.%A+#$RLM7W1E54`;SD<P=N'D0N*Z!R=#@B
M9NLAB[;@(:DS8>9C11SY$4L<,HNC,K*KCIU4D`-T(/2_2HT69B9$KP02QO-&
M;.JLI9#UZ,`;J>A[;=AJK-1JDTTI7!C`4HF,.Q2@(B/W`'B(_P"#2E4K5+W1
M[V@^=4>Y52Y-8MZ:.DW-4L,18D(Z0(0%#,'RT0\>)M'I4S`84E!*<`$!VU)R
M<+,PF5,R*6%F%P'5E)'B-0%Q\14?&S,3,4MB2QRJIL2C*P!\#I)L?@:JO4:I
M%-*52:M\HR%K;T->YU1&\NV@R#2F*V&(3MCE@!%E1?-ZX9X$PLS!)NH852HB
M0"D,.^Q1VDC"S&Q3FB*4X8-C)I;0#TZ%[:;]1TOWU'.7B#)&&98QED7":AK(
MZ]0M]5NAZV[C56:C5(II2FE*I>VW>ET&-3F;U;ZO2X=5TFR2EK;/Q5<C%'JJ
M:JJ3,C^8=LVIW2B2!S%3`_68I#"`;`.I.+AY>;)Z.%%)--:^E%9S8=ILH)MU
M'6H^3EXN''ZN7+'%$3:[L%%SW78@7^%5`T=M7[5L^8N4'C)X@DZ:.VJR;AJZ
M;.$RJH.6SA(QTET%TC@8ARB)3%$!`1`=1V5E8JP(8&Q!Z$$=H(\17>K*ZAT(
M*D7!'4$'O%=C7%<TTI32E4M.T^%L3I%W)("JL@@#=,P=/@D"AU-O$HC^-0=2
M8<N?'4I&;*3>OAHT<W8=:_%E3(J/)Y34[@&X^UHN*;IF/COXM7":B(;_`)`#
M1\J60ZGMJ\1T/SB@C4=!V5]N*-5'1@44@X\BH"!@5:H>C.!P\0.06QDP*8!\
M0^X=%S<I!99&M\>O[=<>E&>MA>JF00!ND1(%%503#I*=<XJ*](>``=0?>.(!
M]H[B/VCJ,>IU=]=E4]9K4PJZ+4[PIUEWRID&+1$2^<Y5(`&4VZMB$21*("<X
MCL&X!XB(!JNO<3W-X[[;8F-+O)>3<,Z4Q8V/';U)G47<BY"K'&""[L;+=0`6
M8`YG9=CS=[F=,:RPQ+J=S>R@]!V=22>P#MZ]PKZB;(C)*I-U6QV3A=,RR"9U
M2JE63(7J/T*%*7<Y`\1`0#P\=2.,<]P^03QX63"V)N$T9DC1G5PZCJ=+`#S*
M.I4J#:Y%P#;C<-GEPE,J.)8%:S$`BQ/9<'N/C52"`#MN`#L("&_V"'L$/N$-
M;[6'JDY2EPTVY!U+`Y?*$W!(BJP@B@0P[B1%(H`5,!'V[>(C[1'4F++F@73#
M90>WIU/X376T:N;M<UU28ZIZ91`L*V,8?WZOF*F`?O`#GZ/\6VOL[AF$W,C6
M^:N!#$.X5PUQ]7&CUO((MNAPU73<(B0J29"*)&`Q-B$3*```AH^?DO&8F:ZD
M6/;7(BC#:@`#6N%]3O.SQ\"<2\:-IJ2CJCDWD@C'W6,8.3MT9UK$U\PQ23\A
M1Z':,<[E#N4DU`.F5R1-02B9,HAZ"_5OQ\<;YNFY,BME8VWWC)%])9O-;P)"
MA21UTDCL)JB/?R69MFV_;E=EQLC-\X4VOI`TW\0"Q(!Z7`/:`1;MQ9Q-CSM^
M=_G)&!<`IV:J8*#BK)6>R4Q2P2EA&7"/QC"WQ0SE>8=JKR+IO/L#N6@K*"+<
M[A5-,Q$CB36P<GW3/YW[&8^^[[Z<N]_:@5)-"I:\S1?B@``H=+6'4`$W(O6$
MX]MF#POWDGV?9?4CVAL`EHR[/>T(D/TB23J6X)/2Y`L#65?CQWXN$'):[5BA
MT@,GU^6F:YE:YV-W>ZS$0</CJF8CJ+VY3=DNDBPLDTBW:R\5&N18)-/5N#^F
M.98B)13%2KN0>R?->.8<N;FC&DC22&-!&[,TLD\@C5(P44W5F746TCJ-)8W`
ML;8_=WB&_P"2F+A-.KLDKN715$20H9&:0AVZ%5-M.H]/-IN+]?C1WYN%O)_/
MU5P!58;,].DLD2CV$Q1>LA4AA!T7(\LQ!R`1\.]:6"4E&#F25:G2:`\:(@HO
MTHJ"BN8J0]G(O9'F7&]BEWW*;#EBQU#3QQ2EI85-NK`HJFP-VTL;#J+J"1U[
M#[P<4Y!O2;)C+E12S,5ADDC"QRL+BRD.S`DBPU*MS8=&(!P,7CB?`<Z>ZAW7
M\(<A'<@^Y))T:YO^%,58K9)5F)-)0";%_CQ!FH8X-'D(THSB-6!HJ15KZ)9\
MY\HRA#')=V'RF7A/MEQ?>M@"CCIGC&XLL:NUF)$Q/>&,@<:NAU!%O8@&GLWC
MD/+_`'#Y'M&],QW\0.<`-(R*"MC%:QM81Z#IL1I+M:XN,W>!^2,GVF.)'!'C
M/SJ;62TYAR3;)W"=*?8H799`@X]LWN;%O2VEAL$[(55RC'P]?N<:TZD$'(I)
M-A(4#`0HFIG>^/)[H\JWSDG"/3CVG'B3)D$]XF8F,F0HJJX)9XW;J5N6!-KU
M;FS;T_MWQO9]@Y<7DW2>1H(S%9U`$@$89F9+!4D1>@:P%A>U75QW=3X[R=OY
MPTMO7,J!*\`*_.67-BJE<@P92\?7S3!7I,>JDM!UIUR?X(L*97B<<4P"7<P;
MCMK,GMER*/%V7+9\7T]]D5,<:VNI?3;U?R=E'G%]):U;"GN!L3S[MCA<C7LT
M;//Y5L0FJ_I^>['R&VH+?I4+X1[ZO!W.Z-[D:T[R17X#%6!+'R#R?8+A564>
MPI=<KUIC:L%4=)QDY,.I>^2Z\NU7:L6!'*1TG2)!6!<XHER^]>RW-MC:"/)7
M&DGRLY,6%4D8F1W0OK&I%"Q*%8,SE2""=.D7.*VGW:XCO(FDQ7F6#'PWR969
M``B(ZQZ"`S$R,6!4*"""`&U74?OPW[X/$3FAFV,P'4*_F'&EZMT?*R^,QRS4
MHF!A\E1\,U>/WP5J1AK'8"$D`CHQTX21<%2(NFU5*FH94@I:XY=[-<LX?LS;
MYEOB9.%$RK-Z#LS0EB`-89$Z7*@D7(+`D`=:XXO[L<8Y5NHV?%7)@S)%+1>L
MBJ)@MR=!5WZV5C8VZ`]]A7J=YGA3@7D_Q1R3EG+<-/2EPXNX3SQ?\2N(FQOH
M5E'61>EHRYUYABU`49MH+ZH,A\E;W>DAR_OQ'7Q[1<PWSC?*,;:MJ>-<3<\W
M%BG#(&+()"ME)ZJ;2-U'?8]U=ON?Q;9]_P"-Y.X;DKME8&%DR0E7*Z6,8:Y`
M^D-4:&Q\/C6%7M%U[@OP+X$T_NR9H;W*,RFZE,IX>4<U^3>S)[9\5OCV%AJK
M5J$==C#GG'<96B*&757;I(I-EEU52D`=K@]U\CFW-^=R^UVS>BVV!89[,`HC
MM&K,[R6+:0SV``))*J`3:JJ]L8^)<.X/%[B;MZRYY,L1(9F+WD951(R0NK2O
M:2!8,20*SE\/.\5Q-YC1687,"6^XAGL#TM[DO)54S-`-:W+Q.-XY$[B0O#-2
M(DY]B_A8Q$$_5%!0CI$5T?S1BJIG-2O+O:CE7$),19Q!EP9TPBA?'<NK2GH(
MSJ5"&8WT]"IL>O0BK;XQ[F\:Y1'E-`9L:7#B,LJ3J%98@+F0:6<%0+7ZW%QT
MZBHKXQ]^;A;RESU5\!5B&S+1I?(TF]A\3W')%*CX.DY)DV0N"ECX:08V"6?L
M'LBJU.FU(\;(%47Z4#F3<'*D.5Y)[(\QXUL<F^Y+8<T..H:>.&0M)"#;JP**
M"`#=M)-A<@%1>L=L'O!Q3D.\ILN,N5%+,Q$+RHJQRD7%E*NQ%R++J`N;#HQ`
M.%?C;W#,$]NGN"]X*_YBA+[9%+KR$"*KM:QM6$9N9>$BLDY&/-RTF^D7T-7X
M.*B_B[8HJ/'B1W#APFDB10XCTW'R/@&]\_X%Q+!V=H(_2P+N\KE5%X8=*@`,
MS,VENBJ0`"6(%55L?.=GX3S;E.7NXF<29H")&NHV$TVIKL510I=;W8$D]`>M
MM@7/W>&XB<;X7B[:<@#DQY4N6]*#(&,K)4Z82P-&%;,SKSTBEJC4I="P-)%0
MEG;)E:,6<@N9?K(!=P#>A]A]IN6\BEW/&P!C#*VF;TID>322]W'D.G01Y&.I
MF46L;U<V]>YW%]AAV_)SFG^J[G%ZD+I'J\ED/F4'6#YQY55CV]*ZW'/O'<1>
M16`^1O(MF;(6,Z+Q:<$+E5GDJM-(^R,V4@D[/6WD5%0$O8`D7%E<LU&;9F"A
M'82`>0=,HF*8W._^TW+-@WW;^/N,?(SMS'Y`Q.2A(MK#,RI8("&9K:=/F!Z&
MS9/<[C.^;/G;Y&9H</;S^6$J@,`;Z2`C/?60547U%NENH)I?A3WK^)O./,(8
M'H]?R[C?(<Q"2MEHL?EBJQ,&RR'7XA!5V^<UE_"6*PHF>I1J"SL$''D@JW05
M,D=0R9RED\Q]GN5<,VC[;S7Q,C;U=4E,#LQB=C8!PR)TN0MQ>Q(!`N+]'$_=
M7C/+MT^R,-<F#.92\8F15]51U)0J[]P+6-N@-KVK%1V-N2&).('"#N!9_P`S
M2JT#CVC<M9I:44BX\9&9DWTE!5B)A8*!BD3)&DIN9EGJ3=ND)TT^I3J4.FF4
MYRVC[V<>W7E/--AV+9D#YT^UJ!<Z54!Y&9F;K954$D_"P!-@:]]I=]V_CO$]
MZWG=G*8,&YM<]IZI$JJH\2Q``Z`7N2!<C+UP3[Q/%_GUD&P8DQS`Y3QUE"%K
MBEU84[+=;BX!W:Z81=BD>?K+Z&G;`P>`@E*M5E6ZAT5?3KE52\Y(ISEJ7G'M
M1R;@F#'NFX-BY&VO)Z9D@=F"26)T.&1"/HL+@$7%B02`;'X?[F\>YGF/MV`N
M1!N")K$<RJI9.GF4J[C\8="02.H!`)$`3GU$?`6O99MF-W[+.#FLU>9LM41S
M)#8V&9QO:+K5B.!=UBK*,9A2SR;F4<H%;L%?AQ$G"JZ1S"FV4*XUGH/83G61
MM46XH<(9,J)(<=IM,R1O:SO=="A0;L-=P`1U8::P\WO7PR#<I-O?ZV88W9/7
M6+5$TBB^A+-K)/0*=%C<$D+YJZ-/RQP0S+W5N,>338YY#5_FQE#B9&Y!QZO9
M4F,/0JWBFQTF\2GR_>8`D^NZCKVS@U)%%PB5LN1)T9,OFCL(ASE[7SC:?;#<
ML`9&!)PW&W4Q2A+M*\R21+JC;0`T1;00;@E;^7N/9C;GQ+<^?X&68<R/E.1M
MRRQZP%18GCE.F1=1(D"&0$6(#6%[U[=J^H4X%U'/,IA>01S`YKU?O2F-;'GB
M.I#-UAN&MR$BK&.4E)8)XEC=0C1RV6\QZE&F`R2)UDB*H!YNNO%]A^<Y>QKO
M$7U09$D'K)C&0C(9+7'ET:`Q!'E+]"0"0>E?.3[T<-Q-Y;:9?K/HI+Z3Y`0>
M@K@D$%M>L@6/4(01U%QUJ5N;7>IXG<&\GL\-W:%RKD[(GRW%W2R0V(:U%3[2
MEU&81%W'2]CEYN?KS!,[R-`'9$6YEQ*U4345,D51/JQ?#/:#E/-=M.[XC8N-
MM_J-&C3NRF21>A5%5'/0^6YMY@0`;&V1Y;[J<:X?N"[9EKD9&;Z8=EA56]-"
M+AF+.@[.M@2;$$VN+Y'<`YUQQR8PYC[.V))A6<Q[DRO-['6WSEHK'ORME55F
MKIC)QZVZK"6BI%JLU=(B)O*<(G*!C``&'0-[V;<..[M/LFZJ$W#&DT.`;B_:
M"#WJP(8'O!%;QL^[86^[9#N^W-KPITU*;6/@01W%2"I'B#6"?ZH))-7MV5+S
M$R*`7DMCT0`Y"G`!&EY+#<`,`[#L.KM_5L_Y_F_HV7^<AJI/?PE>$Q,O1AN,
M77^\FJY&Y]VCB]P:A.+.!LV165C6BX\4,:Y)@Y"C4E&VPR\8G4'4;'P)$64P
MC.JV29EJLJT;(ILCMP471,JLDD*AT]=QO:[DW-)]TWW96Q?JL.ZS0L)9#&P/
MJ!BW52NA5D!)+`]"`I-@<UD^Y''>)Q[=LN[#(^MS;=#*I2/6I!1@%Z,&U,T9
M4>72"1J8`DB1<<=Y3B%D#A7>.=+I:]TO%..;@YQ[:*W9(%@ID,+UU0YH>L0L
M+#3$G%33^QMK`S5:&3?%1*FH<RYT2HJB7&[C[2\NV_F4'"`L$VYY$(E1T<^E
MZ7FU.S,JLH0HP:ZWN/*&)6\[;_=#B^X<4FY?JECVV"7TW5E'JB3RD(%5BI+!
MU(.JP!)8@*;=[@AW>N,G/R\6;%F.X3)^-\IUF`+</D++E;CZ_*S],,Y8MS6.
MN.8B:GH]^@V"5:*+(G417!%TFJF51'J4#XYO[5\EX)AQ;EN#8V1MDLGI^K`Y
M=4>Q.EPR*03I8`@$74@D&PKLX?[E<>YGER;?@+D0;C&FOTYE569.GF72S@CS
M+<$@V-P"`2,JFJTJP::4II2FE*:4J%LOU2=FTH:8KR)WCV$.Z*JQ(8`57;NO
M)$3H`8Q2G52.@&Y=P$Q1\/$-A\9_K>>U/.>;8&S\R]O(VR]^V*28/B*0'FAR
M/3U-$"0&DC:);I<,RL2MRMC9'MYO^V;7-D[?N["/%RE6TA[%9-71O`$-T/8"
M.O;>O`QU#W5[.LY*P1KJ'C8LBYB%>E%%R[<*HG03321-^<(BF!Q,8Q@`!V``
MWW\-*_5VXM[U;[S3%Y+S_;<C9N.;5'(57)NDV3-)&T2HD1\PC0,7=W`!(55O
M<VRO,MRXUC[9)@[3,F1F9!6Y3JJ*""26[-1M8`=>I)M:KB-?H#514TI32E-*
M5J[?4Y_]P>!W^\\Y_P"PH_7I7]7#_;M[_HX?X350/OQ_L^T>'UUO_8JA<C#M
M]2'E[\O"2V?X-N/2.INW_P#^>\3^F4_XJHN;_P!<I_Z-;_A350=AFEX)DNSU
MR/?YSBX=GC*=R)GEIF>P"9>&DW.-8W&].2GT75CASM;"DW9UU5V1(&ZY5"`J
M<$MC*#O']],G>X_=K;X]D9VW-(,8XZ]&`F,TFDA&NERX6]Q8V%^ROOV<P]F?
MVNS3NZ(-NDER!D-U4F+T8]=V6S6"W[#<7-NIK%ZAF&.R_P`R^SJIAKCR]X^<
M+:-R!?TGB,SL5GD[+>[_`%YGFNLO<CW*Q+2;]^Z9LW-R?>6T1%5QY:@.$Q<+
MBF(EL<;2^T<0Y<-VSQG\QFP!)G%45(HF.-((8U"@`D1BY-A<:3I6]JT#[47<
M^6\6.UX1P^*19K)AZF+22*,B(RNUR;`N;`=;$,-36Z9:>]1A"LWJ:2[@/"G+
M=$<\R.`Z\;.9BK]"M-?G[0GCRMS#T2.;C!0KYT]8S=!>$?)N6K\B8OH0SYHJ
M`^0FGJK/9[><G`A^XG,\6<<0WT%<=Y4=4]5U'_9LP`*RC3I9"=,FAEMJ9JL?
MW5VF#,D'->)Y,/WIV4AIEC=6;TE8W]1039HSJN&MJ36K7TA:M=[E?*6$YH8T
M[&')"%8H1)\A\C3*V*";K"NE7;K"73$<!<X)(YA%0S6.L<8X*W,?WU&PIG'Q
M-K:?;CC,W#]PYKQV4EAC;>`C6MKC:.=HV([B4(+`=`;BM?YUR&'E6%Q#?80%
M]?.\RCL5UD@611WV#@VOU(L:\.G?V@?J<O\`RDR;_ER-KOR__!?;;_>X/]37
M3C_^*\__`-UF_P!=5:UJO045]*]9I.,AXN/DIRLR4A,R+-BV;OI5ZKRP9M%'
M<B[23*X>KG:L44NI0QA\I$A/PD*`0)YYYOUG8HY79HDE`4$D@#Z@38`]`+DG
MIWDGOJ9C00P_J[.\2*KO$2Q`L6/UZW4]I-@!U[@!W5&W!7!/-[.O)#M$<A;K
M@>AT+`_';#%;I-.N,;EFB*SUZQHE6KBK#WE[1W]G3MQ9.1>3(`HT:LE/+$YC
M"4`ZMLESC?.%;'L7+-@PLZ>??-PS7D>,P2A(Y2Z!HQ($].P"]"6%^GPJ%PW:
M.6[OO/&=ZR\**'9L'!2-'$T1:2/TVTN4,FNYU=@7H>X5M!]Q7^P-S0_W7LY?
M^G%BUYLX!_SSL]OTGC?SR5?O-O\`DW=OZ.R?YEZTL,LJ*D^G=X5@B`*'-SJO
M(D0,8"IKJ$7S:=%)01\`(=4``1'V;Z]B;4%/O]O!/;]B1=?#_9NOS5Y-W5W7
MV.V<)UON\G3QL,GMJ\2\X,YO.KWW/^9_*+!M'P6UR=VW<B4D]>IN6J/<SLI6
M/K.)X*$ZX2*M,K;TDIJ`JAW*JSEL1!,QP)U`!DP'3<#>^%)@<9X;QG-FSGQN
M1PR:I()([@O.S>9D6.ZLX4!23TO;M-;EN&S\M?-Y'RSD.'%AQY''YH]"31R6
M(2%5NJR,_F6,DDBW=WBKW>W%PSXX<AN&':'S5EO)DO1<F\;9'(%HPY78RW5"
MO-;S,*<A)2P?#)2'GXQ[+6%`)B`;)^7'*MU1!R8HF$QRB&F>X?+>0;!S#ENS
M[5CI-MVXK$F0[1NYB7ZH$U!E8*GE=CYP1T![C6U\'XML6]\5XSNFZ3M%GX+2
M/`HD1!(WUDM8JP);S(H\EC8V[ZQ9Y&`IHCZF<XE*)_Z1L9`!^D.H`-RHES"`
M".X@43%`=OO`/N#5H;?;U/;;P^K3_P#`K5>YO9[@7_R\/_&O5Q-P*4V0OI>B
MF*4P?+&/QV,`"&X2.'S`.P@(;E,&X?<(:P.'_L'N9_G)?\')K,977+]O+_Y&
M/]O%JT5R8R?%7ZC`J1C)@/*/#Y!*F82%$A^4M_ZR"4H@`E-TAN'V[:VHJOWG
M]ON@Z;9D?\#'6N,2./<[`Z#[3@_XV6KS,<E*Q[H'8)!F0C4%.V]BM)3TY"H]
M::F-,X%4(?H*'64Y5#`._P!@C]^M1SP']MN=E^I'(YSU_P`]C5L>!Y?</A87
MI_\`8(/F,&56-5B(AV2^?>PB'_R0T;?81#<`818[&V$-PZ@#V_;JP\G_`*R;
M%_\`KTG^$U:?C]/:[=P.P[^G\VM9B\%HHM^_YQ>3;HI-T_V:F."^4@F1$G2G
MA1RDF42)@0HE322(4H;;%*0H!X`&U1[V;^Q>Z%NI^\,W;_O`_P#3\]6=LX`]
MV]LTBU]BB[/\P:P[X^OM,E>+/$KC=&3+-QGV%[T3^V2V*4DUBW9E77Y:Q7V<
MVYBA1*L1DK,D]$!S#OYZ)D]MTS=-L[A@Y</)=UY#*A&PR</T+/\`^[+`NQ4-
MXZ?,1X$'OJL=MSL1^/[7L,;K]M)R@,T/9(`41`Q7MMJLM_$6[JSYY%'_`/3Q
M@7\O$":_V)S!_F#5'X%C^K9G>'VLO\YCU<&;_P!?</\`HL_X&16O?A7"W-+E
M'PUY.\><`X,HUOQ(\YM.LCV?*]ARG2:%-060:Y7U8QG2V;"[V2!9/6+N!D4W
M`N"=1P,L<@;^(!>V\[QP[C'+MMW_`'[-GBW0;*(D@2&256B9]1D)C1B"&!%C
MX`U26R;7RSD?%<_8]FPXI=N.ZB5YFFCC*NL8&@"21`;J0;_$B]9@N?F-<E=O
MWEY0.XS9<2LL^\6,S<=:-QAY=T04&\RM6XEW0JQCRQL'!^I:./%V2.KS$\>]
M,<6+M\BLQ742*Z;JFJ7@NY;;SSBL_M_BY38')L3<9,W`DZJ'82O,A[F!0N^I
M?I*I610=#`6CS+`S^%<EAYU/C#,X[E8,>)G1V#:5,:1,#^+I8(FDGRLP*,5U
M*3LU<5C\?7/'S%<KQ8B*E!8"L%6:V7&L92(M"%KK:$L2R\RJ#6);II%CG9I)
MZN+Q`Q2JI//-*H`*`8->=.2C?5W[*CY,TK[ZDI28R'4Y9++U8]HL!I/85L1T
MM5];`=G;9\>38%B79WCU1",!5"L2W11:QN3J%KAK@]:PF?4_?_795/\`>5Q[
M_L9DK5S?JV?\_P`O]&R_SD-53[_?\D1?TC#_`($U6^V<A#][/LU%4(10`X"U
M\W2<H&`#DQEG4Q#@!@$`,0P`(#[0$-PUGH!?V;YA_3K_`,]C5KF4?_ZYQ7^A
MX_YG+K"T\V)V*L_$('00W=?:)&(3W""F3$Y#$3,4NQ13*)`$"^P!`/NU<48U
M>]V`6Z__`(O_`*^JP8:?:/<-/0?>(=G^[+6X1B'A9QM9\S*-S3:9-DTN2#GC
M=2L?.,3I6NGE@TZFG0:_#)S'R8E&DN`+EC&20E6,Z%L'@/1L!=O)&[\OY"W$
MIN(/CI]WAN,DHFT2:B_JNVGU-7I_2)Z:=7=>O46W\8V->3Q\F6=AOAPDC,6M
M-.@1JM]%M?9;OT]AM6535:5OU0GDS+;?'\PPBE@0$SR,+(!YN_5L+IPV\/>+
MX;H:S6V[2V?"THO96M^P#_;J)D9*P,%/>+U143R`5G7Z49$,$Y!ZMN)4&Z9C
MB1,OXUUSBJ5)LV2#Q.HH)4R!XB(:F3;"N/&99FTH.\_VO$_`=:ZDS0[:%%R:
MJ=[G>JPO0Q=2;2?GU3IH_#JV(.VB+A0P$(V^([F2=.!4,!1!'K][P`-1$V/,
MFNZH8\<==3]"1XV[1\M=K9D2>4D&3P%2JUG?);Q(3HMH^5FU?*91)%.MR*HI
MBL9L0NXG74:H$$ZYP`")[#OL`;CB6CU,_H7:-.UNP6[+_*>P=IJ2&[`]@Q[J
MJ,#%-[!`1^T`$!$/#?8?RZZJ^JY$0`!$1``#VB(AL'[HZXN*5Y"\JD=2081Z
M[1:98MTG)HY944U#)+@(MU#!^,K=R8AB%5`#$`X"`^("&OL+Y1(]Q"3:X_9M
M\1VUQ?J0/I>%1*EG"KO7#B&4D$*M96:ZC56.LP>G:&=I&$AVIY$#`DW/U!X&
M4Z`'</`0'?67.S94:";09<9A<,G4V\;?W*BC+B8E"0L@Z6/C^&J5F\\N:X]&
M/FXY)@YZ?-2!0O6BZ;C^!TR<IJF;O6BG[U1,QB#]^_AJ9C[&F2GJ0M=>SX@^
M!':#\#76^9Z9TL+']O\`!7W7>0+.>GH:%3*VZY:2:1Y.D!`W4Z5*F'3[X^/O
M:XRMA;'QY)R3Y%)^84CS5>0)WDVK'KWL^`68.=^`\9-\`OX(,O8-R:ADJLUV
MRODX>)M[5:*<1<C$(S;DAV$9--UO3.FHNQ3:+`B=)11/K*<-X]G.>;5PC?IV
MWU)/LC-QO2=T!9HSJ#!BHZE;:@VGS"X(!M:J]]U>%[GS#984V5T7=<2?U$#F
MP<$690Q\H:X4@MY>A!(O<6:\/>"7<-R?SCS!W!^<U0QOB>[RV`['B"F8XHD[
M%2P6&9E:.UH\?(K_``BPVR/@(1I&,U%5E'$BHNL\=%Z$DT":V_EG-^![9PS#
MX'PJ7)R\),Y9Y)I59="B0R$"Z1EV+$``(`%!N2U:QQ7B/-MPY;D\UYA%CXV4
MV(T,<,;`W8Q^F&NKR`+IN3=[EB+`"I)X-=M'DCC3L_<GN$&76=9H^8LOO\V'
MJPL;0QL\`D2YT^KQU76DYB#\])LV=3,*=)T4H'410$3]([@`P>;>X_'MR]V=
MNYIM1EFVG$&/KNA1CZ<CL^E6M<A6!'<3TJ=Q+@>][?[99_$=P"1;GD^OH\P9
M?/&BH6*D@`LI!ZDVZ_"L?6".U]W5DK_VPY#,6,,,0^,>"N3"MVL96\B02E[:
MT57*47?;#:;,J63>PMC>/A,=./;1IR+`BQ$5TBJK@)MYWSW+]L#M_)8]HR,U
M]RWO&N2\3"(R"!HT1!I#);IK+]+MY20+#2MH]O\`W%3<./2;I!B#;]GR.@21
M?4"&=)&=SK96N/HA.OELP!:]2-R$[=7=!P#R;YZ6KA#1<8Y<PWW#(BV1EQ>V
M2Q5R!L5!;Y!?3$C/MPC;-9*OZ>:A7MFE$V;U,)-HLS=$.HB"Y-BX[8/<#VVW
M_C>QXW-)LK$WC8'C,81'993$%"]41[JP1"RG0P92`=/4SM\X1[@;)O\`O$_#
MXL?)VK?$=9-3*K1>J6+='D2Q4N^DC6"""1?H.KESLT<SJ+P?[=>.<(LJ'DW.
MO%W.]TS1D&O/K6T@:JC,Y`GZ[;632)F)Y:'1F8&J/JPU9/Q3.W7=`HHL@00U
M];5[P<1S>9\@S]Y^L8VR[GA1X\3B,L^F)'C)95#%6D#EE)!"V`8TW#VMY1A\
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M>\WW^VX23;.L\9^CH<I]76&0A6MYE\Q4&P)`[+UL>W<'W.3VG^Y6<4BW0PR#
MZ5U#>NTL=V6XL?*&M>US:Y%60<'^V=W#Y+EOPDRCS!I^*\48N[?F)CXOQ^>D
MV]A9K#DQO%M[:VKAW36'EIHC=PH[M!5GSMQ\/2,U9E(FV%94XEW3FGN1P*/B
MV\[9Q27*RMSW[+]:7U$9$A+:"]BRK<62R@:SJ:Y:P%]4XCP3FYY%M.?R9,;'
MV[9L3T8]#!FETAPI.EWL?,"Q.D66P6[$UL5<Q<;VS,7$[DIB>AM&K^[9*P9E
M&C5)B^?(1C)W8[339B&AVSN1<_Q=@W6?O$RG6/[B91$P^`:H+B6XXNT<IV[=
M<XD86-G0R2$"Y")(K,0!U)L#T[ZNKDV#D;GQS/V[#`;+R,.:-`38%GC95!)Z
M`7(Z]U:[TGV>.5%S[+^+^(,DRI]:Y-X:SO9LV05;<VN.D:G84G5DNI4H`UNC
MR.8MB_DJY;A70.KLB1RB"2QDRG%0E\Q^[G&L/WAR>61>M)QS+P4QF<1D.MDC
M.H(;$@/'8VZV-P"18TG+[7;]E^U.-Q=Q&F_8N6TZJ6!5KM(-.H$J"5DN.MKC
M22+DBJN._:^YKYYRKSQY'<Z(_'.&;]RJXLS/&2JU#'TPE:V42YE*Q4:XWNTB
M6*DY]JPB(E&A,#@V!^NY=+.%S=*)")E-$Y![E\.V':MCX]P@Y.;@[7NBYCR2
MJ4+:7D<QC4J$EC*PU:`%`'5B21+V3V_Y5O&Y;SOG+_0Q<O<MM;$5(B'"ZDC3
MU"%+BP])3;6223T4`7@;BIVH>Y`_S?V_:QR<J.':%@'MRVZR6>GWBIV]A9;+
MD="1R(3)R<>C&,GSY^HK(61DV136<M(@&L?UF4(HX`"FSO*/='V^39=^R>-R
MYD^^\AB1)(I(RB0VB]&^H@#HA8D!I+O:Q"UAN.^W/.'W39<;D"8T6R['([H\
M;@M*#,)@"`Q)\ZJ`2L=EN2-70RE<>U9S.F8[O8MV%(J!U>;USI,UQ]*?(5?2
M+.Q\'G:1OD@>P&.?_551.M.2J%*[V$ZNZ8>]K'8GN?Q"%^&%Y9@-E@D7*_)-
MY2V*L0T_N_.+>7NZUD<GV\Y-*O+=$<=]WFB;'_*)Y@N2TIOU\OD(-FMUZ?&I
MBL';<Y82-O[&\PVJ-7%CP8@ZFQY$G/>(,BE><1+S'BSXM=2$_5;2D2KKH2BT
MZ@,)2@'X@UBL?W%XO'B<UB:277O;N<7\FWF#":VK]Q]-?I5D9^"<A?(XC(L:
M:=GC1<GSKY2#!?3U\W1&^C>Y`'?>HUQ_V@>45AQ;WDL8Y`:4ZC'YG9/AK]Q_
MFQMK&?8R"]2RI?,CP@6E"$*Y?5QK(^N8-EA43451*Z.<"'%$2CD-P]V..0[G
MQ'<\`S3#9\9HLI=!4@2010MH+6#$6<BUKZ1U%ZA8?MEOL^!RG;\T1Q?:V4LN
M.VL$'1/+,NK3<J#=`;BXU'H;=?C@?VZNX:^YG\3N0/-6GXOQM1^#/'IO@7&C
M.EVF+LT[D5I`5^W5>JO'S>$E)Q%NX12N;AV]>KG8E/Z9%-)L!CG,7CG'N#P*
M/A^Z[%PZ7*R<W>]P^M3&1&18B[QNX!94N/R055`;Z1)?H+_/#N"<T;E6V[WR
MN/'@QMGP!C1:'5FE")(B$A6<`VD)8DKV`!>I(H'''9@Y92W;3YK\6KXRIM)R
MUE+DY'9XQ`C\XQ\[7)]G6T80Z$5/S,(1V%?4G&[5VV2,J0WD.#I**!Y8&$)^
MZ>\/%X_<;9N2X/KS[5C;:<:?\F592Y;S*&MJTDJ38]1<#K:H^![7<A;@NZ[!
ME>E#N>1N`R8;L&4Z5068J3;4`P%[6)!(`J;>!7!KGG%\U!YW\ZXC$N&!PSQ8
M:X)I476K/%3C293K-10JS:Y6<\7-34;#PL=!MWKZ266>HBHX7(5%!)!,1#"<
M[YOPE^''A/"&R\P9NYG)D9T92NMRYC34JLS%M*H-)Z`W8L:RO#>(\PCY,.5\
MO&+B_5-O&/$J,K7T)HUO9W`4#4S$L#>U@%[,37%;/')/CC"97[A]BX'<>.9E
M+J.?,BREOYY,Y`]=O<S(35F0AK%8<>+RRA'!:FA(2(-8R2;51KZ4'`HJ'\%3
M!:7)]DX[R*;%X#C;YN&T9DV!$L>VD:HE"IJ1)=(MKTC4Z-.=5@P'47KGC^\<
MAV&/)YIE[-@[IBQ9LA?<%\KMJ;2[QZSJTW-@R0@#40>\#.!C+".6.3_=/XI=
MU;'-79%XFVWAY&-2RTQ98=K=HJ:ME&OB:$,\IY%3OUUX]_:&[==9$3H=0',4
MPD+OJFMRWO:^,^V&Z>V&X2,>4P[L3I5&,;+'+%YA)8``A"0#8]@M<U:^!M.?
MR'W"V[W$P4MQZ7:U%V90ZEXY;`I>]P9%!L".TWZ5BWNG9>[E_P`(ROP;J$5A
MI]Q$RMRS9<C#Y_DK6W;VF)8MV3^!:H/*L#\D\9TTKS\AW,>E&+^;(M0\EV5!
M0QM65A^\/MWZF+S7+;-7E>+M1Q!BA"48W#$A[:;%P;,9!Y#U34`*KW)]J^=+
M'D<2PAB_=K(W$9/U@MYU4*4`*ZM1LI!*A#YAT:W6K\>>'#KNUN<EYJJ/%ZPU
MW/\`Q&Y#X!BL&%Q-EF_,X>)P=M6*M6IJQUZK3LE#1:4X#FLGD&,DU^("F:17
M(HW\PA#&T?@W+?:P;;AYG)HI<#EFWY[9/KP1$MD^=W5'=0S:?.%9#HOH4AK$
MBMQYCQCW(?.R\7CTD69QG.P1C^C,X`Q_(B%U5F0:[H65AJ^FP*W`-+"VYO\`
M:^QAV?\`B+AFYT:<B;QE@<.9[($'#V&0L-BN-X97^894A*?;HS3*L5BL2,\F
MI*)IH@FFD@JJ!#J$*#&DX7[D[ERWE>\0SI/#B^OC>9D"I'$8E,FFZEW<1$(;
M]2P%P":YF7EGM_@\8XUM3Q202Y/HY/0,2TDJR-HU`,$16E!>P_%)M<"KT^^'
MPWSUSBX=U_#O'B`A+'>F&:JG=73&P6>,JC(E>AJY=HUXX+)2YDVJC@KJ;;E*
MEOU&*83!X%'6I>R_+]DX5RN3=]_=TPVPI(P50N=3/&P%EZVLIZ_W:VCW7XQN
MO+>,Q[7LZ*^4,N.0@LJ^55D!-V(%[L.E_'PJ(9O@;R6>=S3MQ\G6]6KY\1\;
MN)T3B7*TK\WPY9B+NS6CY3@W#*)@#&!_.LB2-K9%!R@`IF*<Q@\"#K*Q<ZXZ
MGMOR+CADD^U=QW5IX%]-K-&9(&!9NQ39&Z'KT'C6'FX7OLGN#L7(!&GV9@;<
MD,S:UNKB/(4@+>[=9$L0+&YZBW6Q2G]E[EG/=J_DCQ3N;*F4W-T_S`7Y)XIC
M_G"/FZW98V/K$#!(P\O8(@CIO`.YAD,BDB*Q!*BX*B97I3,8Q=US?>+C&/[F
M[=R?",\VSIM(Q)SZ95T)=VU*K6U!3H)MW:@+D"^IXGM5R*?V_P!QX[E^E%ND
MNY_6H1K#*P$:)9F6^F_G`OWZ;V!-I]X-<#^X8YYJW_GYRYJV+,4Y(K_&3^@S
M%-)HT_%V3YCLL93(>HP%CF#,Y2Q145%(MX4RSGSWIC+O'8`1!)NEXX'FO..`
MKP^#@W%),K*V]]Q^L322(R:$+M(R+=48L2P"V6P"]6+&L_Q+B7-FY1-R[DZX
MV/EI@B&**-@VJ01K&)#9W4"RDD$WNPL`!68;HYM_H">7YU1_3\_1^Z?/VJWR
M5^D%\M[=>WE?*'P7YD_X'HNC[.C547X=]][VE^Y'U[L\_J?5M7\?5I_OOEJR
M[<F^ZEKI]ZOJO[S3ZUO_`*?;_>_)5H/<?R6-*R[1XT'/DBZQPD^Z>L2B.]GG
MD.K8/^:UN7MUMPS-IG<B]LFW\A343D>9]7RT2]KQW_E&K!2\DI)&/5C$II5M
M'KCYCMJW6%NF\$HB)3/Q1Z#O2IA^$JHG*3[`#6]?=V$R>JR!I1V$];?P;]GR
M=M8+[6?3H#>7]O\`#X_+5S=$SO4,"0S:_P!\!&QY8F&1'>/L:&<""=3C7:('
M9W.^G+N,4ZD4%`/'Q^WK!;""HE3\TAR:ON&R9G(9CM^WWBVA&M+-;_M&';'%
M^Z`[&;Z.KIUL0<K#N$.WQ_6,BS9C"ZI^Y'<S>!/:!VVZ]]2YCSDV[J>.+=RT
MRY*!,V.U/']"PM7W!_3H23UI^<GGL6Q*($8UV,<`1)91,/P(*E$PJ*E$V'W#
MC296Y0\2V=?3QX@)<EP+D`_1#'O<CL!\1T`4VE8VZ>EBONV8;N_EC'CXV'<`
M>GR'MJXJO<BG=8B.&]9G97S[CGZ:/9K(JJ<"K'B)]"1=H"=/V(MWDM.,TD2A
ML4I&PE+X%UK^1QU,F?>,N%+8F`FA!W:D(!^4*K$_%OC60CW)HTPXG-YL@W/X
M#<_MD?-5?K9N+9<YY_XZ)R1VL]&XZB[#2S)+@FX3E1K23B61:&#8_J&KJ29.
MB`'V`H/L`=8Y=E.-L6W\@TW@?)99;]EM?0GX$*R_-4GZZ)<Z?;[VD6,%?PVZ
MV_!<&K2)CDN_S%@Q'-M$E30>;N/BK=+)46P,0B[JJR!P:OIM)CL8C^!.\;E<
M+)'(9-`2.$S``=`FVV'C<>S[Z=ESDU[+N`/HL>YQU5;]S6-@;W-U/PK$ONAS
M,#Z[`VG-Q_I@?N3T)MX=_P`+$5%%BY`5?DU`!-USTM:Y!5^/,:8IJ2P)QV6(
M5@B)UW5-4.8/-MT8@F*@1I]W#A`#$1%82I@&6Q=CRN+Y'HY.J7CTC>60CK`Q
M/02#_)DFVL=`>IM<U$?<8MSBU1$+N"CJO<X'[G]\+?1/=TZ]*M23Y+2I(XT0
M:956BNHQB1SLXN&S5;V&79I.`.:/<!]ID13,/L-N'AK;#QR`R^NJ`3>(Z$_`
MV[1^'Y*Q/VLX706.CP_L[ZDSCYFD9G.^'HCUHJ!)9'JC$2>8;WO42J"8E]OV
M[ZQW(MH]+8,R73]'&D/S*:D;?N'J9\*7[9%'[-;(`>P-O9L&O.H[*L;LZ5SK
MFE-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*53UNJT'>:I9Z39V)
M)2M7"O356L,8HHLDG(P5@C7,3+L%%6YTUTB/(]VHF)B&*<H&W`0'7?C9,^%D
MQYF*VC)B=71NVS*0RFQZ="`>M=.3CQ9>/)BY`U02HR,/%6!##IUZ@D=*UXX_
MZ<3$D:B]QPVYF\M4N+,E;26N2XSM[6P:5&262>(NDFL@_;D)'NE2E;ID%X,4
M#T?+*IYH+%*H%]2?K`[K*5W%]HVH\H6'TUS"A+CI:X'TAVGR^IIZD6L2#2R^
MR&UKJPAN>Y?=]IO4.+KLA-]5C;R'L`OZ>JP'6X!K8-Q[0JEBRBT_&M"@V5:I
M-"K<-4:G7X\%`90U>K[!",B8YN*QU5U"-638A!.H8ZB@@)C&$PB(T1G9N7N6
M9+N&?(TN;/(TCN>UF8EF)MTZD]U@.X6JYL/#QMOQ(L##01XD,:HBCL55`"@=
M_0#OZ^-5AJ+4FFE*BZV85Q7>LAXRRO;Z3#V#(>&E;0OBZSR(.5GE*<W2*3@[
M.[AD`<%8IO)>(1*W.L=(ZI4_`AB[COD<7=]RPL#)VS$F:/`S-'K(+6D$;:D#
M&U[*W4`$"_;>H.1MF!EYF/N&3$KYF+K])SVQF1=+E>Z[+T)M^"I1UCJG4TI3
M2E-*4TI6KWWQ+[\J<E,3L?.\H'&#F[O8#;;[WVWH[[?;_!:]+>RV$<GCN4X'
M9FD?Z*.JEY_G#%W6&,D`G'O_`"VK#$EFI1NJDNB]$BJ*J:R1]RFZ%$S`=,X%
M.!BB)#%`?$!#<-7`VT%E*L!I(K11O`4W#"X_#7M1&6%K796322LI6)YJ3*:9
MLLNY5<%CVRIQ6EYV054,==V+%F51<Q?>46$G04!,8`&--MGU/%9X8]6A?*B@
M"Y[%4=PN;#P'::[HMT7(G"2.!J/5B3T'>Q\;#K\>RI0R_P`IW.9;?6ZW4DG4
M50ZLQA\8X;J`G#SHVO`Z1CV3R033.*:ULM\FM\0E%@W%1XX$@#T)D`,9M'&1
MLV'+E9A#9TK--D2>+V)('_PXQY4'<HOVDU*S>0#.G2#'-L=0(XE[P.P7_?,>
MK'Q/P%7,9ZY;L3<YZ&E!2Q5*=Q_NN(\15I1)<IFQH[&$O"PUD>H"79,4I&Q)
MR"@&V]Y/HW]FM:V/BLAX/D&=+9F?#/._3KJG5F0&_>$TCX&]9;<>0Q_>*..-
MQZ.-)'$IOW1D!CX=6U?):O<SYS)<X8[G>1\HM7IUF./<V%A9AN@L)@?U.&81
MU3M48&QMC@XATG)2A[`5`H_8&NK8^(KO/MIC[8R@/D8>I2>YV8O&?D:U_A7W
MN7(QMW+)9R?+%/9A^]`"L/FO\M1%;.2#WBOS`RDYJBS6Q5!I=[7'/J^LOO`Y
M&P[?%/C!8%[T#Y9XZQ4Z:04;J@`BW6%)8GB0-\KB\?7E/$,495X\PP1D./IP
MY$7EUC]\DBD$=XN#VU$R-[&S;Y,(BK0"1A8]CQ/U`_`RD6/=VBK<KUE&%K%V
MD@HUB=O:IZU*>H4T"YFTJ6O/3!(0/K#(*`LQL,*00:NP*8#)/FRG2.W2(['@
M;=D9>"HSHU7*TZ95[5U#HUNXHWTE\5(O6*RMSA@R",>2\!\R&]CI/9>W8P[#
M\15*R>=WTS(.Y62D/42#]8SEZY]Q([ITIL*SM<$BD(9TY4`3JG``%10PF'<P
MB.I4.R+!&(8EM&.@'@/`?`=WPKHDWKU&+LP+'M^)\?EJXKA?E?XIR\XQQOJ1
M-Z[.&.FG3U[[^?86:?3^7??6`YEMICXCN<A'T<&4_P`@UD]BW-9=ZQ(P1=LA
M!_*%;QNO%8[*O^FN:4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*5JH]^+BOS`SMR=Q%9^/''[(.6JG#X':
MP,U.U%*(481UB#(-TD#Q#@9"6CU@=DC7:"P[%$O0L7QWW`/4'L?R7B.R\:R\
M;D&X8^)E/G%E635<IZ48U"RGI<$?(:\^>[FV\LS=^QY-AP)\K%7$`9DM8/ZD
MAT]O:!8G^$.WNP@_LZNY[^I7FS_JM9_G+JZ/OY[:?IK"^=O\2JJ^P?<?L^QL
MSYA_=I^SJ[GFW]BO-?[@M:S_`#EVT^_OMI^FL/YV_P`2GV#[D#_R;,^8?W:]
MJN\!^Z55Y^#LD9PKS0$E7I:/G(TRK.M'23D8ITD^8+')\R[&!!V@0^WL$2_=
MKHR>;>V.5COC2;UA^G(A4]7[&%C^)X$UVP;/[DX\Z9";-EZT8,+@6N#<7Z^-
M=']GQW1S2`2BW#/."[\7_P`35=*MZV===\+KUBCE50;+N995SN<QO:)A$==G
MWY]L1%Z2[QA"/3IM=N@M:P\GA7Q]B>Y1D]0[/F&2][V'4]MSU[S59Y6X2=T;
M*&3<A9'?<*,WD=WVY6*VN4UFU8%4BL]*.9$R:@DLHDZB@OL.WN^'AX:A;5R_
MVRVS;<?;UWK"*P0H@ZO^*H'[CX5+W';/<?/SYLP;+F`2R,W4"_F)/7S>%>%9
M>"/=0M;N,?RW"[-:[V-KM?K/JA;ULRSMA6(U&%AU')C67<SAM#M&[;JW'J(@
M41\=]2,;F?M?BHR1;SA!&D=[7;H7.IK>3O8D_+75D;3[EY!5I-FR]:QJM[=H
M4:03U[=(`_`!5/?LZ^Y[[/T+,V;#XC_%JUMN/C_XE^_4C[^^VGZ:POG?_$J.
M=A]R/T-E_,/\:G[.ON>^'_LLS6.W_1JU_.73[^>VGZ:POG;_`!*X^P?<C]#9
MGS#^[5T/"'@EW#Z3S)XLW&_<2LN5:CU;/&-9VWV640KY(V!KL=96+B5EY`R$
M^NL#1@U*913H(8W24=@$?#6L<VYG[?9O#]TP\#=L27-EP9EC12UV<H=*CRCJ
M3T'QK8.*;-SZ'DV!-G;3E18:9<1D=@+*FL:F/7L4=3\`;=>E;Y6O#U>N::4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
LI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
